Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (March 3rd Preview)
-
Theravance collapses: Phase 3 flop triggers R&D shutdown
Theravance announced a decisive strategic retrenchment after its norepinephrine reuptake inhibitor ampreloxetine failed a pivotal Phase 3 study in multiple system atrophy and related neurogenic orthostatic hypotension populations. The company said it will wind down its entire R&D organization and cut about half of its workforce, leaving commercialized respiratory assets as the primary near-term cash generators. The Phase 3 miss closes the book on ampreloxetine after prior late‑stage setbacks and forces management to prioritize financial stability and cash-flow generation. Theravance cited expected annualized savings and indicated the board is exploring strategic options, including a possible sale. Investors pushed the stock down sharply on the readout. For industry watchers, the move underscores how repeated late‑stage failures can force mid‑cap biotechs into survival modes that reshape pipelines and M&A dynamics.
-
FDA rebukes Regenxbio: rejection cites controls and surrogate endpoints
The FDA issued a complete response letter rejecting Regenxbio’s gene therapy for Hunter syndrome, explicitly faulting trial population heterogeneity, inadequate external controls and reliance on an unvalidated surrogate biomarker. Agency reviewers told Regenxbio the RGX‑121 pivotal study did not provide adequate and well‑controlled evidence to support approval. The agency asked Regenxbio to demonstrate either normalization of a relevant disease biomarker or meaningful neurodevelopmental outcomes in a resubmission. The FDA’s letter details shortcomings in trial design and advises options ranging from new late‑stage studies to supplementing the existing cohort. The decision reflects growing agency scrutiny of externally controlled and surrogate‑based submissions for rare disease gene therapies and signals sponsors may need tighter controls or additional clinical endpoints to secure approvals.
-
FDA pressures uniQure: sham‑controlled trial urged for Huntington’s program
The FDA has strongly recommended that uniQure conduct a prospective, randomized, double‑blind, sham surgery‑controlled study before it will consider approval of AMT‑130 for Huntington’s disease. Company disclosures show the agency was unconvinced by data from single‑arm studies with external controls and recommended the gold‑standard trial design. Markets reacted immediately: uniQure shares plunged and analysts warned the requirement could delay the program by two to three years and raise ethical and logistical questions about sham surgery controls. UniQure said it plans to request a Type B meeting with regulators to clarify next steps. The episode highlights regulators’ renewed insistence on randomized controls in certain gene‑therapy filings and the operational, ethical and valuation consequences for sponsors and investors.
-
Intellia cleared with conditions: CRISPR trials resume under tighter monitoring
The FDA lifted clinical holds on two Intellia Phase 3 trials of its CRISPR‑based gene editing therapies after a prior safety event, allowing enrollment to resume with added liver‑safety measures. Regulators required exclusion criteria for patients with specific liver issues and tighter monitoring of hepatic enzymes, plus steroid guidance for transient enzyme elevations. The holds followed a serious liver toxicity event that resulted in a patient death; Intellia and partner Regeneron worked with the agency to define safeguards that balance patient safety with trial continuity. Analysts called the conditions modest and noted timely resolution reduces disruption to development timelines. The outcome illustrates how agencies may permit trial continuation after serious adverse events when companies and regulators align on risk‑mitigation measures.
-
Ascendis wins FDA nod: weekly dwarfism shot cleared on accelerated basis
The FDA granted accelerated approval to Ascendis Pharma’s once‑weekly TransCon CNP (Yuviwel) for children with achondroplasia, clearing the company to compete with BioMarin’s Voxzogo. The decision was based on improvements in annualized growth velocity (AGV) and includes post‑marketing confirmatory requirements to verify clinical benefit. Ascendis received a rare pediatric disease priority review voucher alongside the approval and plans a Q2 commercial rollout. Analysts see modest 2026 uptake with potential acceleration in 2027 as EU filings and label expansions progress. The approval shifts the treatment landscape for achondroplasia by adding a less frequent dosing option, forcing clinicians and payers to weigh convenience and long‑term safety data across newly competitive therapies.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.